IgM nephropathy; can we still ignore it.

Area of Science:

• Nephrology
• Immunology
• Glomerular Diseases

Background:

• IgM nephropathy (IgMN) is an under-recognized glomerular disease.
• It is often considered a transitional form between minimal change disease and focal segmental glomerulosclerosis.
• IgMN contributes significantly to renal morbidity, particularly in developing countries.

Purpose of the Study:

• To review the clinical presentation, response to treatment, and underlying pathophysiology of IgM nephropathy.
• To highlight the importance of IgMN as a cause of kidney disease globally.
• To discuss potential therapeutic strategies for steroid-resistant cases.

Main Methods:

• Comprehensive literature search of major scientific databases including DOAJ, Google Scholar, PubMed, LISTA, and Web of Science.
• Review of studies focusing on clinical presentation, treatment outcomes, and immunological aspects of IgMN.
• Synthesis of findings to provide an overview of the current understanding of the disease.

Main Results:

• IgM nephropathy commonly presents as nephritic syndrome, but can also manifest as proteinuria or hematuria.
• Approximately 30% of patients respond to corticosteroid therapy; the remainder are steroid-dependent or resistant.
• Alternative treatments such as Rituximab or stem cell therapy are suggested for non-responders.

Conclusions:

• IgM nephropathy is a significant cause of renal morbidity, with a higher incidence in developing nations.
• Abnormal T-cell function, specifically hyperactive suppressor T-cells, is implicated in the pathogenesis of IgMN.
• Further therapeutic trials targeting T-cells are needed for steroid-resistant IgM nephropathy.